Filing and reporting period
The supplied filing is Organovo Holdings, Inc. (Nasdaq: ONVO), not Vivosim Labs, Inc. It is a Form 10-K for the fiscal year ended March 31, 2024—not a 2022 fourth-quarter report. The filing provides annual comparisons with fiscal 2023; it does not provide separate Q4 results.
Business context
Organovo is a clinical-stage biotechnology company focused on FXR314 development for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, and on developing 3D human tissue disease models. It formed Mosaic Cell Sciences in February 2024 to supply cells for internal research and potentially sell them to external customers. The company reported no Mosaic product revenue in fiscal 2024.
Financial performance and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $109,000 | $370,000 |
| Research and development expense | $5.5 million | $8.9 million |
| Selling, general and administrative expense | $9.7 million | $9.2 million |
| Operating loss | $15.1 million | $17.7 million |
| Net loss | $14.7 million | $17.3 million |
| Cash used in operating activities | $14.7 million | $12.4 million |
- Revenue was royalty income from a patent license and fell 71%, reflecting lower sales by the licensee. Revenue was immaterial relative to expenses; a meaningful operating margin is not indicated by these figures.
- R&D expense declined 38%, primarily because FY2023 included $4.0 million of acquired FXR program in-process R&D expense. FY2024 SG&A increased 5%, including higher investor-relations and legal costs.
- At March 31, 2024, cash and cash equivalents were $2.9 million, current assets $3.9 million, current liabilities $1.9 million, and working capital $2.0 million. Accumulated deficit was $339.7 million.
- Total liabilities were $2.7 million, including $1.4 million of operating lease liabilities. The balance sheet reports no borrowings or other financial debt.
- Cash and cash equivalents were approximately $7.0 million as of May 29, 2024, after subsequent financing. The filing reports $4.7 million net proceeds from a May public offering and approximately $1.8 million net proceeds from ATM sales after March 31.
Material changes, outlook and risks
- Management planned to start a Phase 2a UC trial during calendar 2024. It said FXR314 Phase 2 MASH data released in April 2024 supported ongoing development, but the provided filing text does not give the trial results or clear numerical efficacy or safety values.
- Management forecast approximately $23.5 million in total operating expenses for fiscal 2025. It expects substantial additional financing will be needed; the company’s ability to continue as a going concern depends on obtaining funding, reducing expenditures, grants, or generating revenue.
- Management and the independent auditor both identified substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for a possible failure to continue operations.
- The May 2024 offering raised approximately $4.7 million net through common shares, pre-funded warrants and accompanying warrants. The financing and subsequent ATM sales dilute shareholders; exercise of warrants could add further shares.
- The company expects about $1.5 million in annual savings from an August 2023 workforce reduction; it incurred approximately $0.4 million in severance costs in FY2024.
- Key risks include clinical and regulatory uncertainty, limited cash and continuing losses, dependence on further financing and collaborators, the unproven commercial model for 3D tissue discovery and Mosaic, human-cell supply, competition, intellectual-property risks, and potential Nasdaq listing and share-price volatility.
Important facts for investors to verify
- Confirm the issuer and period: this summary is based on Organovo’s FY2024 Form 10-K, not a Vivosim Labs filing or 2022 Q4 report.
- Check the status, timing, design and results of the planned UC Phase 2a trial, and review the full April 2024 MASH data.
- Assess cash burn against the reported May 29 cash balance, the FY2025 expense forecast, and the company’s continuing need for financing.
- Review the offering and ATM terms, outstanding and exercisable warrants, and potential share dilution.
- Monitor Mosaic’s launch, customer demand, revenue and costs; no Mosaic product revenue was reported for FY2024.